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Abstract: The syntheses of C-13 epimeric 3-[(1-benzyl-1,2,3-triazol-4-yl)methoxy]-D-secoestrones are
reported. Triazoles were prepared from 3-(prop-2-inyloxy)-D-secoalcohols and p-substituted benzyl
azides via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC). The antiproliferative activities of the
products and their precursors were determined in vitro against a panel of human adherent cervical
(HeLa, SiHa and C33A), breast (MCF-7, MDA-MB-231, MDA-MB-361 and T47D) and ovarian (A2780)
cell lines by means of MTT assays. The orientation of the angular methyl group and the substitution
pattern of the benzyl group of the azide greatly influenced the cell growth-inhibitory potential of the
compounds. The 13β derivatives generally proved to be more potent than their 13α counterparts.
Introduction of a benzyltriazolylmethyl group onto the 3-OH position seemed to be advantageous.
One 13α compound containing an unsubstituted benzyltriazolyl function displayed outstanding
antiproliferative activities against three cell lines.
Keywords: antiproliferative effect; azide-alkyne cycloaddition; D-secoestrone; triazole
1. Introduction
Anticancer drug design based on synthetic modifications of naturally occurring biomolecules
may lead to nontoxic drug candidates with selective antitumoral potencies [1,2]. Estrone-based
anticancer agents are already utilized in therapy, but one of the most important requirements of these
drugs is a lack of original hormonal activity [3,4]. The literature provides evidence that inversion
of the configuration at C-13 or the opening of ring D of the estrane core may lead to the loss of
estrogenic activity [5–9]. We recently reported that 3-benzyl ethers of D-secoestrone alcohol or
oxime (compounds 1 and 2, Figure 1.) exert substantial in vitro cell growth-inhibitory action against
a number of cancer cell lines, with IC50 values in the low micromolar or submicromolar range [10,11].
Compounds 1 and 2 were diversified at several sites in the molecule, including different modifications
(etherifications, esterifications or debenzylations) at C-3 and/or C-17 and epimerization at C-13 (only
in the case of 2). It was concluded that the nature of the 3- and 17-functional groups exerts a great
impact on the antiproliferative behavior of the compounds. 3-Ethers proved to be more potent than
their 3-OH counterparts. Derivatives containing a 17-oxime function displayed more pronounced
cytostatic properties than those of 17-hydroxymethyl derivatives. 3-Hydroxy-D-secooxime 2, but not
the D-secoalcohol 1, was further derivatized by introducing a terminal alkyne function onto the 3-OH
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group by using propargyl bromide, and the resulting steroid alkyne was subjected to Cu(I)-catalyzed
azide-alkyne cycloaddition (CuAAC) with different substituted benzyl azides. The triazole moiety is
frequently used as a linker in bioconjugates, because it is a good mimic of peptide bonding with high
proteolytic and metabolic stability [12–14]. Introduction of a triazolyl function into the oxime 2 led to
improved antiproliferative properties as compared with the 3-benzyl ether. The benzyltriazolylmethoxy
D-secooxime 3 (Figure 1) exerted substantial cell growth-inhibitory effects against several human cancer
cell lines.
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Figure 1. Structures of the potent antiproliferative D-secoestrones 1 and 2, 3. 
The abovementioned outstanding results suggested that it might be useful to introduce the 
benzyltriazolyl function onto other positions of the D-secoestrone scaffold. In a continuation of our 
earlier work, we focused herein on the synthesis of steroidal alkynes bearing a terminal alkyne function 
on the opened ring D. The D-secoestrone 17-carboxylic acids were reacted with propargylamine using 
peptide coupling reagents [15]. The reactions were carried out in both the 13α- and the 13β-estrone series 
in order to obtain more compounds for structure-activity determinations. The resulting N-propargyl  
17-carboxamides were reacted with small molecule azides, such as substituted benzyl azides, and the 
resulting triazoles were evaluated for their antiproliferative activities against several human reproductive 
cancer cell lines. The activities of the compounds depended greatly on the substitution pattern of the 
aromatic ring of the benzyl azide moiety. 3-Benzyl ethers of 13β-(p-alkylbenzyl)triazoles displayed 
outstanding selective antiproliferative potential against A2780 cells. 
There are already a number of literature examples of the synthesis of antiproliferative steroidal 
triazoles formed mainly from steroid azides and small molecule alkynes, such as phenylacetylenes. 
It has been found that the cytostatic activity of the resulting triazoles depends considerably on the 
substitution pattern of the phenyl group of the acetylene [16–22]. 
In view of the abovementioned recent results, we aimed to introduce the benzyltriazolylmethoxy 
moiety onto the 3-OH group of the C-13 epimeric D-secoalcohols. The synthesis of the D-secoestrone 
alkynes were first planned at position C-3, followed by the CuAAC reactions of the secosteroidal 
alkynes with substituted benzyl azides. The next goal was to perform comparative investigations of 
the in vitro antiproliferative activities of the products and their precursors by means of MTT assays 
against a panel of human adherent cervical (HeLa, SiHa and C33A), breast (MCF-7, MDA-MB-231, 
MDA-MB-361 and T47D) and ovarian (A2780) cell lines. Our main objective was to establish some 
structure-activity relationship, focusing particularly on the C-13 epimeric character of the compounds. 
2. Results 
We first synthesized steroidal alkynes in both the 13α- and the 13β-D-secoestrone series (Scheme 1). 
After removal of the benzyl protecting group of compounds 1 or 6 by hydrogenolysis, an excess of 
propargyl bromide was added in the presence of K2CO3, leading to the 3-(prop-2-inyloxy)-17-alcohols 
9 or 10. The terminal alkynes 9 or 10 were reacted with benzyl azide (11a) or its substituted derivatives 
11b–e under recently published CuAAC reaction conditions [20], furnishing the desired triazolyl 
compounds 12a–e or 13a–e in high yields. The structures of the triazoles were established from the 
corresponding 1H- and 13C-NMR spectra. 
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The abovementioned u standing results sugge ted that it might be useful to ntr duce the
benzyltriazolyl function onto other positions of the D-secoestrone scaffold. In a continuation
of our earlier work, we focused herein on the synthesis of steroidal alkynes bearing a terminal
alkyne function on the opened ring D. The D-secoestrone 17-carboxylic acids were reacted with
propargylamine using peptide coupling reagents [15]. The reactions were carried out in both the 13α-
and the 13β-estrone series in order to obtain more compounds for structure-activity determinations.
The resulting N-propargyl 17-carboxamides were reacted with small molecule azides, such as
substituted benzyl azides, and the resulting triazoles were evaluated for their antiproliferative activities
against everal human reproductive cancer cell lines. The a tivities of the compounds depended
greatly on the substitution pattern f the aromatic ring of the benzyl azide m ety. 3-Benzyl ethers
of 13β-(p-alkylbenzyl)triazoles displayed outstanding sel ctive antiprolifer tive potential against
A2780 cells.
There are already a number of literature examples of the synthesis of antiproliferative steroidal
triazoles formed mainly from steroid azides and small molecule alkynes, such as phenylacetylenes.
It has been found that the cytostatic activity of the resulting triazoles depends considerably on the
substitution pattern of the phenyl group of the acetylene [16–22].
In view of the abovementioned recent results, we aimed to introduce the benzyltriazolylmethoxy
moiety o to the 3-OH group of the C-13 epimeric D-secoalcohols. The synthesis of the D-secoestrone
alkynes were first planned at position C-3, followed by the CuAAC reactions f the secosteroidal
alkynes with substituted benzyl azides. The next goal was to perform comparative investigations of
the in vitro antiproliferative activities of the products and their precursors by means of MTT assays
against a panel of human adherent cervical (HeLa, SiHa and C33A), breast (MCF-7, MDA-MB-231,
MDA-MB-361 and T47D) and varian (A2780) cell lines. Our main objective was to establish some
structure-activity relationship, focusing particularly on the C-13 epimeric character of the compounds.
2. Results
We first synthesized steroidal alkynes in both the 13α- and the 13β-D-secoestrone series (Scheme 1).
After removal of the be zyl protecting group of compounds 1 or 6 by hydrogenolysis, an excess of
propargyl bromide was added in the presence of K2CO3, leading to the 3-(prop-2-inyloxy)-17-alcohols
9 or 10. The terminal alkynes 9 or 10 were reacted with benzyl azide (11a) or its substituted derivatives
11b–e under recently published CuAAC reaction conditions [20], furnishing the desired triazolyl
compounds 12a–e or 13a–e in high yields. The structures of the triazoles were established from the
corresponding 1H- and 13C-NMR spectra.
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Scheme 1. Synthesis of D-secoestrone derivatives (12a–e and 13a–e). Reagents and conditions: (i) 5 equiv. 
KBH4, CH2Cl2:MeOH = 1:1, 0 °C—r.t., 0.5 h; (ii) H2 (20 bar), Pd/C, EtOAc, 3 h; (iii) propargyl bromide 
(1.5 equiv.), K2CO3 (7 equiv.), acetone, 70 °C, 24 h; (iv) CuI (0.05 equiv.), Ph3P (0.1 equiv.), DIPEA (3 equiv.), 
toluene, reflux, 2 h. 
The cell growth-inhibitory activities of the triazoles and their precursors were determined  
in vitro against a panel of human adherent cervical (HeLa, SiHa and C33A), breast (MCF-7, MDA-
MB-231, MDA-MB-361 and T47D) and ovarian (A2780) cell lines by means of MTT assays (Table 1). 
The 3-benzyl ether of the 13β-D-secoalcohol 1 selectively inhibited the growth of MCF-7 cells, with 
inhibition values >80% at 10 μM. Its C-13 epimer 6 at 10 μM displayed <50% inhibition on all the 
examined cell lines. The 3-OH derivatives 7 and 8 exerted low antiproliferative potentials at both 
concentrations (even at 30 μM). Among the propargyl derivatives 9 and 10, only the 13β epimer 9 
inhibited the growth of nearly all the cell lines by >50% at 30 μM. As concerns the triazoles, 12a 
displayed the highest antiproliferative activity against A2780, HeLa and C33A, with inhibition values 
>80% at 10 μM. The p-methyl derivative 12b displayed somewhat lower potential against the 
abovementioned cell lines. Compounds 12c and 12d inhibited the growth of only two cell lines (A2780 
and C33A) by >80% at 30 μM. The 13α-epimeric triazole 13a displayed substantial antiproliferative 
potential against A2780, Hela and C33A. 13b inhibited the growth of nearly all cell lines by >50% at  
30 μM. The other 13α-epimeric triazoles 13c–e did not influence the growth of the cell lines effectively. 
Compound 12a displayed limited growth inhibition against noncancerous human fibroblast cell 
line (MRC-5) with values <30% even at 30 μM. 
3. Discussion 
The benzyl protecting groups of the D-secoalcohols 1, 6 in both the 13α- and the 13β-D-secoestrone 
series were removed by hydrogenolysis, using Pd/C as a catalyst. The saturation of the δ-alkenyl  
side-chain occurred simultaneously. The resulting 3,17-diols 7 and 8 were selectively alkylated at 
their 3-OH functions, taking advantage of the more acidic behavior of the phenolic over the alcoholic 
OH groups. The propargylations led to the desired terminal alkynes 9 or 10 in high yields. The steroidal 
alkynes were subjected to azide-alkyne cycloadditions under the earlier published reaction conditions 
[20], using a catalytic amount of CuI and PPh3 as an accelerating ligand. 
Scheme 1. Synthesis of D-secoestrone derivatives (12a–e and 13a–e). Reagents and conditions: (i) 5 equiv.
KBH4, CH2Cl2:MeOH = 1:1, 0 ˝C—r.t., 0.5 h; (ii) H2 (20 bar), Pd/C, EtOAc, 3 h; (iii) propargyl bromide
(1.5 equiv.), K2CO3 (7 equiv.), acetone, 70 ˝C, 24 h; (iv) CuI (0.05 equiv.), Ph3P (0.1 equiv.), DIPEA
(3 equiv.), toluene, reflux, 2 h.
The cell growth-inhibitory activities of the triazoles and their precursors were determined in vitro
against a pan l of human adherent cervical (HeLa, SiHa and C33A), breast ( F-7, MDA-MB-231,
MDA-MB-361 and T47D) and ovarian (A2780) cell lines by means of MTT assays (Table 1). The 3-benzyl
ether of the 13β-D-secoalcohol 1 selectively inhibited the growth of MCF-7 cells, with inhibition values
>80% at 10 µM. Its C-13 epimer 6 at 10 µM displayed <50% inhibition on all the examined cell lines.
The 3-OH derivatives 7 and 8 exerted low antiproliferative potentials at both concentrations (even
at 30 µM). Among the propargyl derivatives 9 and 10, only the 13β epimer 9 inhibited the growth
of nearly all the cell lines by >50% at 30 µM. As concerns the triaz les, 12a displayed the highest
antiproliferative activity against A2780, HeLa and C33A, with inhibitio values >80% at 10 µM.
The p-methyl derivative 12b displayed somewhat lower potential against the abovementioned cell
lines. Compounds 12c and 12d inhibited the growth of only two cell lines (A2780 and C33A) by
>80% at 30 µM. The 13α-epimeric triazole 13a displayed substantial antiproliferative potential against
A2780, Hela and C33A. 13b inhibited the growth of nearly all cell lines by >50% at 30 µM. The other
13α-epimeric triazoles 13c–e did not influence the growth of the cell lines effectively.
Compound 12a displayed limited growth inhibition against noncancerous human fibroblast cell
line (MRC-5) with values <30% even at 30 µM.
3. Discussion
The benzyl protecting groups of the D-secoalcohols 1, 6 in both the 13α- and the 13β-D-secoestrone
series were removed by hydrogenolysis, using Pd/C as a catalyst. The saturation of the δ-alkenyl
side-chain occurred simultaneously. The resulting 3,17-diols 7 and 8 were selectively alkylated
at their 3-OH functions, taking advantage of the more acidic behavior of the phenolic over the
alcoholic OH groups. The propargylations led to the desired terminal alkynes 9 or 10 in high yields.
The steroidal alkynes were subjected to azide-alkyne cycloadditions under the earlier published
reaction conditions [20], using a catalytic amount of CuI and PPh3 as an accelerating ligand.
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Table 1. Antiproliferative properties of the synthesized compounds. Mean value from two independent determinations with five parallel wells; standard
deviation <15%.
Comp. Conc. (µM) Inhibition (%) ˘ SEM (Calculated IC50)
1
A2780 Hela SiHa C33A MCF-7 T47D MDA-MB-231 MDA-MB-361
1
10 42.3 ˘ 0.9 31.4 ˘ 1.6 - 2 39.2 ˘ 0.6 81.3 ˘ 0.7 26.1 ˘ 2.0 - 28.2 ˘ 0.4
30 97.5 ˘ 0.1 97.9 ˘ 0.3 84.3 ˘ 0.9 86.9 ˘ 0.7
97.4 ˘ 0.3
87.2 ˘ 0.9 84.5 ˘ 0.9 87.6 ˘ 0.4(6.4)
6
10 43.6 ˘ 2.4 20.1 ˘ 1.8 - 40.4 ˘ 2.1 - - - -
30 55.4 ˘ 2.5 60.3 ˘ 1.4 49.7 ˘ 1.4 53.8 ˘ 1.1 36.4 ˘ 1.2 59.6 ˘ 0.8 49.3 ˘ 1.6 77.2 ˘ 1.3
7
10 - - - 40.5 ˘ 0.8 24.3 ˘ 2.6 - - -
30 35.1 ˘ 0.8 40.7 ˘ 1.7 - 42.3 ˘ 1.8 51.6 ˘ 2.9 - - -
8
10 - 23.7 ˘ 0.9 - - - - - -
30 - 64.5 ˘ 1.1 - - - 23.0 ˘ 1.7 - -
9
10 22.4 ˘ 1.0 21.5 ˘ 0.8 - 30.0 ˘ 1.1 - - 36.8 ˘ 2.7 -
30 70.7 ˘ 0.4 89.3 ˘ 1.9 84.5 ˘ 0.5 70.1 ˘ 0.7 52.5 ˘ 1.0 37.7 ˘ 1.3 81.0 ˘ 1.1 59.0 ˘ 2.9
10
10 - - - - - - - -
30 29.7 ˘ 1.9 36.9 ˘ 1.8 - 39.9 ˘ 1.1 23.3 ˘ 0.6 45.5 ˘ 0.6 28.2 ˘ 2.2 -
12a
10 81.5 ˘ 1.1 85.4 ˘ 0.3 21.2 ˘ 1.1 90.0 ˘ 0.3 66.3 ˘ 0.3 51.0 ˘ 1.1 53.5 ˘ 1.2 59.3 ˘ 1.4
30
88.0 ˘ 0.1 91.7 ˘ 0.3
34.5 ˘ 1.2
95.1 ˘ 0.2 74.5 ˘ 1.7
54.4 ˘ 1.8 59.6 ˘ 1.8 45.2 ˘ 1.1(0.9) (1.1) [23] (1.8) [23] (1.5)
12b
10 96.8 ˘ 0.2 52.6 ˘ 0.9 48.1 ˘ 0.8 86.8 ˘ 0.8 71.6 ˘ 1.0 65.7 ˘ 1.4 58.3 ˘ 0.7 87.2 ˘ 0.5
30
97.4 ˘ 0.1
65.4 ˘ 0.9 64.3 ˘ 1.0
93.9 ˘ 0.9 73.9 ˘ 1.0
66.4 ˘ 1.2
86.1 ˘ 0.3 89.3 ˘ 1.1
(3.8) (5.0) (5.0) (8.3) (4.4)
12c
10 83.3 ˘ 0.5 27.1 ˘ 1.7 - 57.5 ˘ 1.8 - - 33.6 ˘ 0.8 47.1 ˘ 2.9
30
93.4 ˘ 0.1
66.0 ˘ 2.4 35.6 ˘ 0.3
84.6 ˘ 0.9
66.1 ˘ 1.7 53.0 ˘ 1.6 48.9 ˘ 0.7 45.6 ˘ 0.6(5.4) (8.3)
12d
10 20.5 ˘ 1.2 30.9 ˘ 3.0 - 25.3 ˘ 1.5 - - - -
30 29.0 ˘ 2.0 45.9 ˘ 1.1 - 64.0 ˘ 1.8 29.5 ˘ 2.7 28.9 ˘ 0.9 - 45.5 ˘ 1.2
12e
10 86.4 ˘ 0.3 46.3 ˘ 2.5 25.5 ˘ 2.0 81.4 ˘ 1.9 61.1 ˘ 1.6 41.5 ˘ 2.0 49.8 ˘ 0.7 47.5 ˘ 0.7
30
89.6 ˘ 0.3
72.5 ˘ 1.1 23.2 ˘ 1.2
88.9 ˘ 0.6 63.4 ˘ 0.9
49.7 ˘ 2.5 48.8 ˘ 0.9 46.7 ˘ 1.0(4.6) (5.4) (6.6)
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Table 1. Cont.
Comp. Conc. (µM) Inhibition (%) ˘ SEM (Calculated IC50)
1
A2780 Hela SiHa C33A MCF-7 T47D MDA-MB-231 MDA-MB-361
13a
10 73.4 ˘ 0.9 70.0 ˘ 0.7 41.8 ˘ 1.7 80.0 ˘ 0.5 39.4 ˘ 1.2 36.6 ˘ 0.7 38.2 ˘ 2.2 65.8 ˘ 1.0
30
83.8 ˘ 0.8 90.9 ˘ 0.3
37.1 ˘ 1.0
93.9 ˘ 0.1
73.8 ˘ 1.1 69.1 ˘ 0.6 59.7 ˘ 1.6 48.6 ˘ 1.4(3.0) (5.3) (4.4)
13b
10 54.3 ˘ 0.8 33.9 ˘ 1.1 - 26.6 ˘ 1.8 - 43.2 ˘ 0.3 36.7 ˘ 1.8 -
30
81.0 ˘ 0.1
74.4 ˘ 0.9 49.4 ˘ 0.8 86.1 ˘ 0.6 65.6 ˘ 1.9 89.3 ˘ 0.8 56.8 ˘ 1.2 48.7 ˘ 1.0(9.8)
13c
10 - 21.3 ˘ 2.3 - - - - - -
30 52.7 ˘ 1.9 40.6 ˘ 0.9 - 41.7 ˘ 1.2 20.1 ˘ 0.8 39.4 ˘ 1.7 28.1 ˘ 0.7 25.7 ˘ 2.8
13d
10 20.0 ˘ 1.9 24.4 ˘ 1.3 - 26.1 ˘ 0.9 - - - -
30 44.8 ˘ 1.1 36.9 ˘ 0.8 23.0 ˘ 1.2 66.3 ˘ 0.6 30.8 ˘ 1.7 44.4 ˘ 1.7 37.5 ˘ 1.6 40.3 ˘ 2.1
13e
10 - - - - - - - -
30 29.1 ˘ 2.3 48.3 ˘ 2.0 - 34.2 ˘ 1.3 - 22.8 ˘ 1.9 - -
Cisplatin
10 83.6 ˘ 1.2 42.6 ˘ 2.3 88.6 ˘ 0.5 83.8 ˘ 0.8 66.9 ˘ 1.8 51.0 ˘ 2.0 - 67.5 ˘ 1.0
30
95.0 ˘ 0.3 99.9 ˘ 0.3 90.2 ˘ 1.8 94.0 ˘ 0.6 96.8 ˘ 0.4 57.9 ˘ 1.5 71.5 ˘ 1.2 87.8 ˘ 1.1
(1.3) (12.4) (7.8) (3.7) (5.8) (9.8) (19.1) (3.7)
1: Mean value from two independent determinations with five parallel wells; standard deviation <15%; 2: Inhibition values <20% are not presented.
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All the CuAACs furnished the triazoles 12a–e or 13a–e in excellent yields. The orientation of the
angular methyl group and the substitution pattern of the N-benzyl ring did not influence the yields of
the reactions, as it was expected.
From the comparison of the 1H-NMR spectra of the 3-benzyl ethers 1 and 6 with those of their
phenolic counterparts 7 and 8, the absence of the proton signals of the benzylic protecting group from
the aromatic region, and the presence of the singlet at around 9 ppm clearly indicates the successful
removal of the protecting group. In the 1H-NMR spectra of 9 and 10, the introduction of the propargyl
group onto the 3-O is supported by the singlet at 2.5 ppm, which relates to the terminal alkyne function,
and by the singlet of double intensity (the OCH2 group of the ether function). In the 13C-NMR spectra
of the triazoles 12a–e and 13a–e, the two OCH2 and the NCH2 carbon signals appear in the 55–70 ppm
range, indicating the presence of the N-benzyltriazolylmethoxy moiety on C-3. There are additional
quaternary carbon signals in the aromatic region of the spectra of the triazoles, belonging to the newly
introduced moiety. As concerns the epimeric character of the triazoles, C-18 in the 13β epimers 12a–e
appears at higher chemical shift (~25 ppm) than that in the 13α counterparts 13a–e (~16 ppm).
The results of the MTT assays of the 3-OH 7 and 8 or 3-ether compounds 1, 6, 9 and 10 revealed
their substantially lower inhibitory properties than those of some triazoles (Table 1). 3-OH derivatives
7, 8 exerted the lowest growth inhibition, thus the presence of the phenolic OH function in the
D-secoestrone seems to be disadvantageous. A bulky apolar benzyl or a smaller propargyl ether
protecting group on C-3 improved the antiproliferative behavior, leading to values >80% or >50% being
attained at 30 µM. Introduction of a triazolylmethyl linker between the oxygen on C-3 and the benzyl
protecting group seemed to be beneficial in both C-13 epimer series. As concerns the triazoles 12a–e
and 13a–e, the 13β epimers 12a–e displayed overall higher inhibitions than their 13α counterparts
13a–e. In both series, the most potent derivative 12a or 13a was that bearing an unsubstituted N-benzyl
group, as observed earlier in the case of the D-secooxime 3 [11]. The characterization of the mechanism
of the antiproliferative action of 12a on the three cervical cancer cell lines in under publication [23].
However, 12a displayed unusual behavior against the panel of breast cancer cell lines, with inhibition
levels <75% even at 30 µM. It can be stated that the presence of an electron-donating p-alkyl or
an electron-withdrawing p-nitro substituent on the N-benzyl ring of the triazoles 12c–e and 13c–e
usually proved to be detrimental for biological activity. The inhibitory effects decreased as the size
of the p-alkyl moiety increased. It may be noted that to date there have been no reports of the
13α-D-secoestrone derivatives with high antitumor activity.
The majority of cervical carcinomas originate from high-risk human papillomavirus (HPV)
infections of the epithelial layer of the cervix, including HPV-16, -18, -31 and -35 among others [24].
HeLa is known to be an HPV-18-positive cell line [25]. SiHa and C33A differ in HPV-16 status, since
only SiHa is infected by it. This pathological difference may cause a difference in antiproliferative
action of the compounds against these cell lines. Our test compounds did not significantly influence
the proliferation of SiHa cells, except in the cases of two ethers of the 13β epimer 1 or 9, with values of
>80% at 30 µM. However, several triazoles were similarly potent against HeLa or C33A, independently
of the HPV status of the cell lines.
Substantial differences in the growth-inhibitory potential of compound 1 were determined against
a panel of breast cancer cell lines differing in receptor status [26]. These cell lines included T47D
(expressing the estrogen, progesterone and androgen receptors), MDA-MB-361 (expressing the estrogen
receptor and HER2) and a triple-negative cell line, MDA-MB-231. Compound 1 proved to be selective
against cell line MCF-7. Since the other test compounds displayed similar activities against this cell
line panel, the receptor status of the cells seems irrelevant, as we earlier observed for certain recently
published D-homoestrones [27].
The cancer selectivity of one of the most promising compounds 12a was tested by means of the
same MTT assay, using non-cancerous human fibroblast cells MRC5. Compound 12a elicited growth
inhibition of 24.9% ˘ 4.9% (mean ˘ SEM) when applied at a final concentration of 30 µM. The reference
agent cisplatin at the same concentration caused a more substantial inhibition (70.7% ˘ 1.3%).
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On the basis of these results, it could be concluded that the selected compound displays limited
growth-inhibitory action against these non-cancerous cells, indicating some selective toxicity towards
fast growing cancer cells.
4. Materials and Methods
4.1. General Information
Melting points (mp) were determined with a Kofler hot-stage apparatus and are uncorrected.
Elemental analyses were performed with a CHN analyzer model 2400 (Perkin-Elmer, Waltham, MA,
USA). Thin-layer chromatography: silica gel 60 F254; layer thickness 0.2 mm (Merck, New York, NY,
USA); eluents: (A) 2% ethyl acetate/98% dichloromethane, (B) 10% ethyl acetate/90% dichloromethane;
detection with iodine or UV (365 nm) after spraying with 5% phosphomolybdic acid in 50% aqueous
phosphoric acid and heating at 100–120 ˝C for 10 min. Flash chromatography: silica gel 60, 40–63 µm
(Merck). 1H-NMR spectra were recorded in CDCl3 solution (if not otherwise stated) with a DRX-500
instrument (Bruker, Billerica, MA, USA) at 500 MHz, with Me4Si as internal standard. 13C-NMR
spectra were recorded with the same instrument at 125 MHz under the same conditions.
4.2. Chemistry
4.2.1. General Procedure for the Synthesis of 3-Benzyloxy-D-secoalcohols 1, 6
D-secoaldehyde 4 or 5 [10] (374 mg, 1.00 mmol) was dissolved in a 1:1 mixture of dichloromethane
and methanol (10 mL) in an ice-water bath and potassium borohydride (270 mg, 5.00 mmol) was added
in small portions. The mixture was allowed to stand at room temperature for 0.5 h, then diluted with
water and extracted with dichloromethane. The combined organic phases were washed with water
until neutral and dried over sodium sulfate. The crude product was subjected to flash chromatography
with dichloromethane as eluent.
3-Benzyloxy-13α-hydroxymethyl-14β-(prop-2-enyl)-des-D-estra-1,3,5(10)-triene (1). As described in
Section 4.2.1, D-secoaldehyde 4 (374 mg, 1.00 mmol) was reacted with potassium borohydride
(270 mg, 5.00 mmol). Compound 1 is identical with the compound described in the literature [10]:
oil, Rf = 0.53 (A). 1H-NMR δ ppm 0.80 (s, 3H, 18-H3), 2.85 (m, 2H, 6-H2), 3.30 and 3.61 (2ˆ m, 2ˆ 1H,
17-H2), 5.03 (m, 2H, 16a-H2), 5.04 (s, 2H, OCH2), 5.93 (m, 1H, 16-H), 6.73 (d, 1H, J = 2.3 Hz, 4-H), 6.79
(dd, 1H, J = 8.5 Hz, J = 2.3 Hz, 2-H), 7.22 (d, 1H, J = 8.5 Hz, 1-H), 7.32 (t, 1H, J = 7.3 Hz, 41-H), 7.38 (t,
2H, J = 7.3 Hz, 31-H and 51-H), 7.43 (d, 2H, J = 7.3 Hz, 21-H and 61-H).
3-Benzyloxy-13β-hydroxymethyl-14β-(prop-2-enyl)-des-D-estra-1,3,5(10)-triene (6). As described in
Section 4.2.1, D-secoaldehyde 5 (374 mg, 1.00 mmol) was reacted with potassium borohydride (270 mg,
5.00 mmol). Compound 6 was obtained as a white solid. Yield: 347 mg (92%). Mp 50–52 ˝C,
Rf = 0.47 (A). Anal. Calcd. for C26H32O2: C, 82.94; H, 8.57. Found: C, 83.05; H, 8.66. 1H-NMR
δ ppm 1.06 (s, 3H, 18-H3); 2.82 (m, 2H, 6-H2); 3.53 and 3.72 (2ˆ d, 2ˆ 1H, J = 10.8 Hz, 17-H2); 4.96–5.07
(overlapping multiplets, 4H, 16a-H2, OCH2); 5.87 (m, 1H, 16-H); 6.71 (s, 1H, 4-H); 6.79 (d, 1H, J = 8.3 Hz,
2-H); 7.21 (d, 1H, J = 8.3 Hz, 1-H); 7.32 (t, 1H, J = 6.9 Hz, 41-H); 7.38 (t, 2H, J = 7.1 Hz, 31-H and 51-H);
7.42 (d, 2H, J = 6.7 Hz, 21-H and 61-H), 13C-NMR δ ppm 25.3 (C-18); 26.5; 27.8; 30.3; 32.4; 35.6; 38.8; 41.2;
43.7; 50.7; 64.5 (C-17); 69.9 (OCH2); 112.4 (C-2); 114.5 (C-4); 114.6 (C-16a); 126.3 (C-1); 127.4 (2C:C-31,51);
127.8; 128.5 (2C:C-21,61); 133.0 (C-41); 137.3 (C-10); 137.9 (C-5); 140.2 (C-16); 156.8 (C-3).
4.2.2. General Procedure for the Synthesis of 3-Hydroxy-D-secoestrones 7, 8
A suspension of 1 or 6 (376 mg, 1.00 mmol) and Pd/C (0.30 g, 10%) in ethyl acetate (20 mL) was
subjected to 20 bar of hydrogen pressure at room temperature for 3 h. The catalyst was then removed
by filtration through a short pad of silica gel. After evaporation of the solvent in vacuo, the crude
product was subjected to flash chromatography with dichloromethane as eluent.
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3-Hydroxy-13α-hydroxymethyl-14β-propyl-des-D-estra-1,3,5(10)-triene (7). As described in Section 4.2.2,
compound 1 (376 mg, 1.00 mmol) was subjected to hydrogenolysis. Compound 7 is identical with
compound described in the literature [10]: Mp 60–62 ˝C, Rf = 0.17 (A). 1H-NMR δ ppm 0.77 (s, 3H,
18-H3), 2.82 (m, 2H, 6-H2), 3.35 and 3.52 (2ˆ d, 2ˆ 1H, J = 10.9 Hz, 17-H2), 6.56 (d, 1H, J = 2.3 Hz, 4-H),
6.63 (dd, 1H, J = 8.5 Hz, J = 2.3 Hz, 2-H), 7.16 (d, 1H, J = 8.5 Hz, 1-H).
3-Hydroxy-13β-hydroxymethyl-14β-propyl-des-D-estra-1,3,5(10)-triene (8). As described in Section 4.2.2,
compound 6 (376 mg, 1.00 mmol) was subjected to hydrogenolysis. The chromatographic purification
of the crude product yielded 8 as a white solid (268 mg, 93%). Mp 50-52 ˝C, Rf = 0.27 (A). Anal. Calcd.
for C19H28O2: C, 79.12; H, 9.78. Found: C, 79.25; H, 9.96. DMSO-d6 1H-NMR δ ppm 0.89 (t, 3H,
J = 6.7 Hz, 16a-H3); 1.17 (s, 3H, 18-H3); 2.69 (m, 2H, 6-H2); 3.19 and 3.48 (2ˆ m, 2ˆ 1H, 17-H2); 4.18 (s,
1H, 17-OH); 6.41 (s, 1H, 4-H); 6.50 (dd, 1H, J = 1.76 Hz, J = 8.2 Hz, 2-H); 7.04 (d, 1H, J = 8.5 Hz, 1-H);
8.96 (s, 1H, 3-OH), 13C-NMR δ ppm 14.4 (C-16a); 25.0; 25.2 (C-18); 26.3; 27.4; 29.8; 30.3; 35.1; 38.0; 41.3;
43.2; 50.8; 61.5 (C-17); 112.7 (C-2); 114.5 (C-4); 126.0 (C-1); 130.6 (C-10); 136.9 (C-5); 154.8 (C-3).
4.2.3. General Procedure for the Synthesis of 3-(Prop-2-inyloxy)-D-secoestrones 9, 10
3-Hydroxy-D-secoalcohol 7 or 8 (288 mg, 1.00 mmol) was dissolved in acetone (10 mL), propargyl
bromide (0.17 mL (80 wt % in toluene), 1.50 mmol) and potassium carbonate (968 mg, 7.00 mmol) were
added. The reaction mixture was stirred at 70 ˝C for 24 h, the solvent was evaporated off, and the
residue was subjected to flash chromatography with 2% ethyl acetate/98% dichloromethane as eluent.
3-(Prop-2-ynyloxy)-13α-hydroxymethyl-14β-propyl-des-D-estra-1,3,5(10)-triene (9). As described in
Section 4.2.3, 3-hydroxy-D-secoalcohol 7 (288 mg, 1.00 mmol) was reacted with propargyl bromide
(0.17 mL (80 wt % in toluene), 1.50 mmol). Compound 9 was obtained as a white solid (280 mg, 86%).
Mp 41-43 ˝C, Rf = 0.40 (A). Anal. Calcd. for C22H30O2: C, 80.94; H, 9.26. Found: C, 81.02; H, 9.35.
1H-NMR δ ppm 0.78 (s, 3H, 18-H3); 0.92 (t, 3H, J = 6.9 Hz, 16a-H3); 2.50 (s, 1H, C”CH); 2.86 (m, 2H,
6-H2); 3.34 and 3.52 (2ˆ d, 2ˆ 1H, J = 10.9 Hz, 17-H2); 4.66 (s, 2H, OCH2); 6.70 (d, 1H, J = 2.3 Hz, 4-H);
6.79 (dd, 1H, J = 8.5 Hz, J = 2.3 Hz, 2-H); 7.24 (d, 1H, J = 8.5 Hz, 1-H), 13C-NMR δ ppm 14.7 (C-16a);
15.9 (C-18); 25.0; 26.4; 27.5; 30.7; 31.2; 35.6; 38.7; 41.7; 43.5; 45.2; 55.7 and 71.3 (2ˆ OCH2); 74.9 (C”CH);
78.5 (C”CH); 112.4 (C-2); 114.5 (C-4); 126.6 (C-1); 133.8 (C-10); 138.1 (C-5); 155.4 (C-3).
3-(Prop-2-ynyloxy)-13β-hydroxymethyl-14β-propyl-des-D-estra-1,3,5(10)-triene (10). As described in
Section 4.2.3, 3-hydroxy-D-secoalcohol 8 (288 mg, 1.00 mmol) was reacted with propargylbromide
(0.17 mL (80 wt % in toluene), 1.50 mmol). Compound 10 was obtained as a white solid (271 mg, 83%).
Mp 41–43 ˝C, Rf = 0.50 (A). Anal. Calcd. for C22H30O2: C, 80.94; H, 9.26. Found: C, 80.87; H, 9.42.
1H-NMR δ ppm 0.92 (t, 3H, J = 6.9 Hz, 16a-H3); 1.03 (s, 3H, 18-H3); 2.50 (s, 1H, C”CH); 2.84 (m, 2H,
6-H2); 3.47 and 3.73 (2ˆ d, 2ˆ 1H, J = 10.9 Hz, 17-H2); 4.65 (s, 2H, OCH2); 6.68(d, 1H, J = 2.3 Hz, 4-H);
6.78 (dd, 1H, J = 8.5 Hz, J = 2.3 Hz, 2-H); 7.22 (d, 1H, J = 8.5 Hz, 1-H), 13C-NMR δ ppm 14.6 (C-16a);
24.9 (C-18); 25.5; 26.6; 27.7; 30.6; 31.0; 35.2; 38.6; 41.7; 43.7; 51.4; 55.7 and 64.1 (2ˆ OCH2); 75.2 (C”CH);
78.9 (C”CH); 112.4 (C-2); 114.5 (C-4); 126.5 (C-1); 133.8 (C-10); 137.9 (C-5); 155.4 (C-3).
4.2.4. General Procedure for the “Click” Reaction
To a stirred solution of 3-(prop-2-inlyoxy)-D-secoalcohol 9 or 10 (326 mg, 1.00 mmol) in toluene
(5 mL), PPh3 (52 mg, 0.20 mmol), CuI (19 mg, 0.10 mmol), DIPEA (0.52 ml, 3.00 mmol) and the
appropriate benzyl azide 11 (1 equiv., see [28–31] for their preparation) were added. The reaction
mixture was refluxed for 2 h, allowed to cool and evaporated in vacuo. The residue 12a–e, 13a–e was
purified by flash chromatography with 10% ethyl acetate/90% dichloromethane as eluent.
3-[{1-Benzyl-1H-1,2,3-triazol-4-yl}methoxy]-13α-hydroxymethyl-14β-propyl-des-D-estra-1,3,5(10)-triene (12a).
As described in Section 4.2.4, alkyne 9 (326 mg, 1.00 mmol) was reacted with benzyl azide 11a (133 mg,
1.0 mmol). Yield: 428 mg (93%). Mp 41-43 ˝C, Rf = 0.46 (B). Anal. Calcd. for C29H37N3O2: C, 75.78;
H, 8.11. Found: C, 75.94; H, 8.25. 1H-NMR δ ppm 0.77 (s, 3H, 18-H3); 0.92 (t, 3H, J = 6.9 Hz, 16a-H3);
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2.84 (m, 2H, 6-H2); 3.34 and 3.52 (2ˆ d, 2ˆ 1H, J = 10.9 Hz, 17-H2); 5.16 (s, 2H, OCH2); 5.53 (s, 2H,
NCH2); 6.69 (d, 1H, J = 2.3 Hz, 4-H); 6.77 (dd, 1H, J = 8.5 Hz, J = 2.3 Hz, 2-H); 7.21 (d, 1H, J = 8.5 Hz,
1-H); 7.28 (dd, 2H, J = 8.6 Hz, J = 2.9 Hz, 21-H and 61-H), 7.38 (overlapping multiplets, 3H, 31-H, 41-H
and 51-H); 7.52 (s, 1H, C=CH), 13C-NMR δ ppm 14.6 (C-18); 16.0 (C-16a); 25.0; 26.4; 27.4; 30.6; 31.2; 35.6;
38.7; 41.7; 43.5; 45.2; 54.2 (NCH2); 62.1 (OCH2); 71.3 (C-17); 112.4 (C-2); 114.4 (C-4); 122.5 (C=CH); 126.6
(C-1); 128.1 (2C: C-31,51); 128.8 (C-41); 129.1 (2C: C-21,61); 133.5 (C-10); 134.4 (C-11); 138.1 (C-5); 144.9
(C=CH); 156.0 (C-3).
3-[{1-(4-Methylbenzyl)-1H-1,2,3-triazol-4-yl}methoxy]-13α-hydroxymethyl-14β-propyl-des-D-estra-1,3,5
(10)-triene (12b). As described in Section 4.2.4, alkyne 9 (326 mg, 1.00 mmol) was reacted with
4-methylbenzyl azide 11b (147 mg, 1.00 mmol). Yield: 436 mg (92%). Mp 50-52 ˝C, Rf = 0.26 (B).
Anal. Calcd. for C30H39N3O2: C, 76.07; H, 8.30. Found: C, 75.92; H, 8.54. 1H-NMR δ ppm 0.77 (s, 3H,
18-H3); 0.91 (t, 3H, J = 6.9 Hz, 16a-H3); 2.35 (s, 3H, tolyl-CH3); 2.83 (m, 2H, 6-H2); 3.34 and 3.52 (2ˆ d,
2ˆ 1H, J = 10.9 Hz, 17-H2); 5.15 (s, 2H, OCH2); 5.48 (s, 2H, NCH2); 6.68 (d, 1H, J = 2.3 Hz, 4-H); 6.76
(dd, 1H, J = 8.5 Hz, J = 2.3 Hz, 2-H); 7.17-7.20 (overlapping multiplets, 6H, 1-H, C=CH, 21-H, 31-H, 51-H
and 61-H), 13C-NMR δ ppm 14.6 (C-18); 15.9 (C-16a); 21.1 (tolyl-CH3); 24.9; 26.4; 27.4; 30.6; 31.2; 35.6;
38.7; 41.7; 43.5; 45.3; 54.2 (NCH2); 62.1 (OCH2); 71.3 (C-17); 112.4 (C-2); 114.4 (C-4); 122.4 (C=CH); 126.5
(C-1); 128.2 (2C: C-31,51); 129.7 (2C: C-21,61); 131.3 and 133.5 (C-10 and C-41); 138.1 (C-5); 138.7 (C-11);
144.7 (C=CH); 156.0 (C-3).
3-[{1-(4-[Prop-2-yl]benzyl)-1H-1,2,3-triazol-4-yl}methoxy]-13α-hydroxymethyl-14β-propyl-des-D-estra-1,3,5
(10)-triene (12c). As described in Section 4.2.4, alkyne 9 (326 mg, 1.00 mmol) was reacted with
4-(prop-2-yl)-benzyl azide 11c (175 mg, 1.00 mmol). Yield: 452 mg (90%). Mp 41-43 ˝C, Rf = 0.30 (B).
Anal. Calcd. for C32H43N3O2: C, 76.61; H, 8.64. Found: C, 76.85; H, 8.76. 1H-NMR δ ppm 0.77 (s, 3H,
18-H3); 0.91 (t, 3H, J = 6.9 Hz, 16a-H3); 1.24 (d, 6H, 2ˆ prop-2-yl-CH3); 2.83 (m, 2H, 6-H2); 3.33 and 3.52
(2ˆ d, 2ˆ 1H, J = 10.9 Hz, 17-H2); 5.19 (s, 2H, OCH2); 5.50 (s, 2H, NCH2); 6.68 (d, 1H, J = 2.3 Hz, 4-H);
6.75 (dd, 1H, J = 8.5 Hz, J = 2.3 Hz, 2-H); 7.22-7.24 (overlapping multiplets, 5H, 1-H, 21-H, 31-H, 51-H
and 61-H); 7.55 (s, 1H, C=CH), 13C-NMR δ ppm 14.6 and 15.9 (C-18 and C-16a); 23.8 (2C: CH(CH3)2);
24.9; 26.4; 27.4; 30.6; 31.2; 33.8 (CH(CH3)2); 35.6; 38.7; 41.7; 43.5; 45.2; 54.0 (NCH2); 62.0 (OCH2); 71.2
(C-17); 112.3 (C-2); 114.3 (C-4); 122.5 (C=CH); 126.5 (C-1); 127.1 (2C: C-31,51); 128.2 (2C: C-21,61); 131.7
(C-11); 133.5 (C-10); 138.1 (C-5); 144.7 (C-41); 149.6 (C=CH); 156.1 (C-3).
3-[{1-(4-tert-Butylbenzyl)-1H-1,2,3-triazol-4-yl}methoxy]-13α-hydroxymethyl-14β-propyl-des-D-estra-1,3,5
(10)-triene (12d). As described in Section 4.2.4, alkyne 9 (326 mg, 1.00 mmol) was reacted with
4-tert-butylbenzyl azide 11d (189 mg, 1.00 mmol). Yield: 475 mg (92%). Mp 58-60 ˝C, Rf = 0.32 (B).
Anal. Calcd. for C33H45N3O2: C, 76.85; H, 8.79. Found: C, 75.98; H, 8.95. 1H-NMR δ ppm 0.77 (s, 3H,
18-H3); 0.91 (t, 3H, J = 6.9 Hz, 16a-H3); 1.31 (s, 9H, 3ˆ tBu-CH3); 2.83 (m, 2H, 6-H2); 3.33 and 3.52 (2ˆ d,
2ˆ 1H, J = 10.9 Hz, 17-H2); 5.18 (s, 2H, OCH2); 5.50 (s, 2H, NCH2); 6.68 (d, 1H, J = 2.3 Hz, 4-H); 6.77
(dd, 1H, J = 8.5 Hz, J = 2.3 Hz, 2-H); 7.20-7.24 (overlapping multiplets, 3H, 1-H, 21-H and 61-H); 7.39 (d,
2H, J = 8.1 Hz, 31-H and 51-H); 7.54 (s, 1H, C=CH), 13C-NMR δ ppm 14.7 and 15.9 (C-18 and C-16a);
24.9; 26.4; 27.4; 30.7; 31.1 (3C: C(CH3)3); 31.2; 34.6 (C(CH3)3); 35.6; 38.7; 41.7; 43.5; 45.2; 54.0 (NCH2);
62.1 (OCH2); 71.3 (C-17); 112.4 (C-2); 114.4 (C-4); 122.5 (C=CH); 126.0 (2C: C-31,51); 126.6 (C-1); 127.9
(2C: C-21,61); 131.3 (C-11); 133.5 (C-10); 138.1 (C-5); 144.8 (C-41); 151.9 (C=CH); 156.0 (C-3).
3-[{1-(4-Nitrobenzyl)-1H-1,2,3-triazol-4-yl}methoxy]-13α-hydroxymethyl-14β-propyl-des-D-estra-1,3,5(10)
-triene (12e). As described in Section 4.2.4, alkyne 9 (326 mg, 1.00 mmol) was reacted with 4-nitrobenzyl
azide 11e (178 mg, 1.00 mmol). Yield: 475 mg, 94%). Mp 65-67 ˝C, Rf = 0.20 (B). Anal. Calcd. for
C29H36N4O4: C, 69.02; H, 7.19. Found: C, 69.15; H, 7.02. 1H-NMR δ ppm 0.77 (s, 3H, 18-H3); 0.91 (t,
3H, J = 6.9 Hz, 16a-H3); 2.83 (m, 2H, 6-H2); 3.34 and 3.52 (2ˆ d, 2ˆ 1H, J = 10.9 Hz, 17-H2); 5.19 (s, 2H,
OCH2); 5.64 (s, 2H, NCH2); 6.67 (d, 1H, J = 2.3 Hz, 4-H); 6.76 (dd, 1H, J = 8.5 Hz, J = 2.3 Hz, 2-H); 7.21
(d, 1H, J = 8.5 Hz, 1-H); 7.40 (d, 2H, J = 8.6 Hz, 21-H, 61-H); 7.62 (s, 1H, C=CH); 8.22 (d, J = 8.6 Hz, 2H,
31-H, 51-H), 13C-NMR δ ppm 14.6 (C-18); 15.9 (C-16a); 24.9; 26.4; 27.4; 30.7; 31.2; 35.6; 38.7; 41.7; 43.5;
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45.2; 53.1 (NCH2); 62.0 (OCH2); 71.2 (C-17); 112.3 (C-2); 114.3 (C-4); 122.8 (CH=C); 124.3 (2C: C-31,51);
126.6 (C-1); 128.6 (2C: C-21,61); 133.7 (C-10); 138.2 (C-5); 141.5 and 145.5 (C-11 and C=CH); 148.1 (C-41);
155.9 (C-3).
3-[{1-Benzyl-1H-1,2,3-triazol-4-yl}methoxy]-13β-hydroxymethyl-14β-propyl-des-D-estra-1,3,5(10)-triene
(13a). As described in Section 4.2.4, alkyne 10 (326 mg, 1.00 mmol) was reacted with benzyl azide 11a
(133 mg, 1.00 mmol). Yield: 437 mg (95%). Oil, Rf = 0.19 (B). Anal. Calcd. for C29H37N3O2: C, 75.78; H,
8.11. Found: C, 75.93; H, 8.02. 1H-NMR δ ppm 0.89 (t, 3H, J = 7.2 Hz, 16a-H3); 1.00 (s, 3H, 18-H3); 2.80
(m, 2H, 6-H2); 3.44 and 3.70 (2ˆ d, 2ˆ 1H, J = 10.9 Hz, 17-H2); 5.13 (s, 2H, OCH2); 5.50 (s, 2H, NCH2);
6.66 (d, 1H, J = 2.4 Hz, 4-H); 6.73 (dd, 1H, J = 8.5 Hz, J = 2.1 Hz, 2-H); 7.16 (d, 1H, J = 8.5 Hz, 1-H);
7.24 (d, 2H, J = 7.6 Hz, 21-H and 61-H), 7.35 (overlapping multiplets, 3H, 31-H, 41-H and 51-H); 7.51 (s,
1H, C=CH), 13C-NMR δ ppm 14.5 (C-16a); 24.9 (C-18); 25.5; 26.6; 27.7; 30.5; 30.9; 35.2; 38.5; 41.6; 43.7;
51.4; 54.2 (NCH2); 62.0 and 64.0 (OCH2 and C-17); 112.3 (C-2); 114.3 (C-4); 122.5 (C=CH); 126.5 (C-1);
128.1 (2C: C-31,51); 128.8 (C-41); 129.1 (2C: C-21,61); 133.4 (C-10); 134.4 (C-11); 137.9 (C-5); 145.0 (C=CH);
156.0 (C-3).
3-[{1-(4-Methylbenzyl)-1H-1,2,3-triazol-4-yl}methoxy]-13β-hydroxymethyl-14β-propyl-des-D-estra-1,3,5
(10)-triene (13b). As described in Section 4.2.4, alkyne 10 (326 mg, 1.00 mmol) was reacted with
4-methylbenzyl azide 11b (147 mg, 1.00 mmol). Yield: 431 mg (91%). Mp 49-51 ˝C, Rf = 0.16 (B).
Anal. Calcd. for C30H39N3O2: C, 76.07; H, 8.30. Found: C, 75.94; H, 8.22. 1H-NMR δ ppm 0.90 (t,
3H, J = 7.5 Hz, 16a-H3); 1.02 (s, 3H, 18-H3); 2.36 (s, 3H, tolyl-CH3); 2.82 (m, 2H, 6-H2); 3.47 and 3.73
(2ˆ d, 2ˆ 1H, J = 10.9 Hz, 17-H2); 5.14 (s, 2H, OCH2); 5.48 (s, 2H, NCH2); 6.68 (s, 1H, 4-H); 6.76 (d, 1H,
J = 7.8 Hz, 2-H); 7.17 (overlapping multiplets, 6H, 1-H, C=CH, 21,31,51,61-H), 13C-NMR δ ppm 14.6
(C-16a); 21.1 (tolyl-CH3); 24.9 (C-18); 25.5; 26.6; 27.7; 30.5; 30.9; 35.2; 38.6; 41.7; 43.7; 51.4; 54.2 (NCH2);
62.0 and 64.1 (OCH2 and C-17); 112.4 (C-2); 114.3 (C-4); 122.4 (C=CH); 126.5 (C-1); 128.2 (2C: C-31,51);
129.8 (2C: C-21,61); 131.3 (C-41); 133.4 (C-10); 137.9 (C-5); 138.8 (C-11); 144.7 (C=CH); 156.0 (C-3).
3-[{1-(4-[Prop-2-yl]benzyl)-1H-1,2,3-triazol-4-yl}methoxy]-13β-hydroxymethyl-14β-propyl-des-D-estra-1,3,5
(10)-triene (13c). As described in Section 4.2.4, alkyne 10 (326 mg, 1.00 mmol) was reacted with
4-(prop-2-yl)-benzyl azide 11c (175 mg, 1.00 mmol). Yield: 462 mg (92%). Mp 47-49 ˝C, Rf = 0.19 (B).
Anal. Calcd. for C32H43N3O2: C, 76.61; H, 8.64. Found: C, 76.85; H, 8.53. 1H-NMR δ ppm 0.91 (t, 3H,
J = 6.8 Hz, 16a-H3); 1.02 (s, 3H, 18-H3); 1.24 (d, 2ˆ 3H, J = 11.4 Hz, 2ˆ prop-2-yl-CH3); 2.82 (m, 2H,
6-H2); 2.90 (m, 1H, prop-2-yl-CH); 3.47 and 3.73 (2ˆ d, 2ˆ 1H, J = 10.8 Hz, 17-H2); 5.15 (s, 2H, OCH2);
5.49 (s, 2H, NCH2); 6.68 (d, 1H, J = 2.2 Hz, 4H); 6.76 (dd, 1H, J = 8.6 Hz, J = 2.2 Hz, 2-H); 7.19–7.23
(overlapping multiplets, 5H, 1-H, 21,31,51,61-H); 7.57 (s, 1H, C=CH), 13C-NMR δ ppm 14.5 (C-16a); 23.8
(2C: CH(CH3)2); 24.8 (C-18); 25.5; 26.6; 27.7; 30.6; 31.0; 33.8 (CH(CH3)2); 35.2; 38.6; 41.7; 43.7; 51.4; 54.2
(NCH2); 62.1 (OCH2); 64.1 (C-17); 112.4 (C-2); 114.4 (C-4); 122.6 (C=CH); 126.5 (C-1); 127.2 (2C: C-31,51);
128.2 (2C: C-21,61); 131.7 (C-11); 133.4 (C-10); 137.9 (C-5); 149.7 (C-41); 150.1 (C=CH); 156.0 (C-3).
3-[{1-(4-tert-Butylbenzyl)-1H-1,2,3-triazol-4-yl}methoxy]-13β-hydroxymethyl-14β-propyl-des-D-estra-1,3,5
(10)-triene (13d). As described in Section 4.2.4, alkyne 10 (326 mg, 1.00 mmol) was reacted with
4-tert-butylbenzyl azide 11d (189 mg, 1.00 mmol). Yield: 470 mg (91%). Mp 58-60 ˝C, Rf = 0.32 (B).
Anal. Calcd. for C33H45N3O2: C, 76.85; H, 8.79. Found: C, 76.72; H, 8.90. 1H NMR δ ppm 0.91 (t, 3H,
J = 7.2 Hz, 16a-H3); 1.02 (s, 3H, 18-H3); 1.32 (s, 3ˆ 3H, 3ˆ tBu-CH3); 2.82 (m, 2H, 6-H2); 3.47 and 3.73
(2ˆ d, 2ˆ 1H, J = 10.9 Hz, 17-H2); 5.16 (s, 2H, OCH2); 5.49 (s, 2H, NCH2); 6.67 (d, 1H, J = 2.2 Hz, 4H);
6.76 (dd, 1H, J = 8.6 Hz, J = 2.2 Hz, 2-H); 7.18 (d, 1H, J = 8.6 Hz, 1-H); 7.21 (d, 2H, J = 8.2 Hz, 21, 61-H);
7.39 (d, 2H, J = 8.2 Hz, 31, 51-H); 7.54 (s, 1H, C=CH), 13C-NMR δ ppm 14.5 (C-16a); 24.9 (C-18); 25.5;
26.6; 27.7; 30.5; 30.9; 31.2 (3C: C(CH3)3); 34.6 (C(CH3)3); 35.2; 38.6; 41.7; 43.7; 51.4; 54.0 (NCH2); 62.1
(OCH2); 64.1 (C-17); 112.4 (C-2); 114.3 (C-4); 122.6 (C=CH); 126.0 (2C: C-31,51); 126.5 (C-1); 127.9 (2C:
C-21,61); 131.3 (C-11); 133.4 (C-10); 137.9 (C-5); 144.7 (C-41); 151.9 (C=CH); 156.0 (C-3).
3-[{1-(4-Nitrobenzyl)-1H-1,2,3-triazol-4-yl}methoxy]-13β-hydroxymethyl-14β-propyl-des-D-estra-1,3,5(10)
-triene (13e). As described in Section 4.2.4, alkyne 10 (326 mg, 1.00 mmol) was reacted with
4-nitrobenzyl azide 11e (178 mg, 1.00 mmol). Yield: 475 mg, 94%). Mp 50-52 ˝C, Rf = 0.12 (B). Anal.
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Calcd. for C29H36N4O4: C, 69.02; H, 7.19. Found: C, 69.21; H, 7.05. 1H-NMR δ ppm 0.91 (t, 3H,
J = 6.9 Hz, 16a-H3); 1.02 (s, 3H, 18-H3); 2.82 (m, 2H, 6-H2); 3.47 and 3.73 (2ˆ d, 2ˆ 1H, J = 10.9 Hz,
17-H2); 5.19 (s, 2H, OCH2); 5.65 (s, 2H, NCH2); 6.68 (s, 1H, 4-H); 6.76 (d, 1H, J = 8.6 Hz, 2-H); 7.20 (d,
1H, J = 8.6 Hz, 1-H); 7.40 (d, 2H, J = 8.3 Hz, 21,61-H); 7.64 (s, 1H, C=CH); 8.23 (d, 2H, J = 8.5 Hz, 31,51-H),
13C-NMR δ ppm 14.5 (C-16a); 24.9 (C-18); 25.5; 26.6; 27.7; 30.6; 31.0; 35.2; 38.6; 41.7; 43.7; 51.4; 53.3
(NCH2); 62.0 (OCH2); 64.1 (C-17); 112.3 (C-2); 114.4 (C-4); 124.3 (2C: C-31,51); 124.8 (C=CH); 126.6 (C-1);
128.6 (2C: C-21,61); 133.6 (C-10); 138.0 (C-5); 141.4 (C-11); 144.0 (C=CH); 144.8 (C-41); 155.9 (C-3).
4.3. Determination of Antiproliferative Activities
The antiproliferative properties of the prepared triazoles 12a–e or 13a–e and compounds 1, 6–10
were determined on a panel of human adherent gynecological cancer cell lines. MCF-7, MDA-MB-231,
MDA-MB-361 and T47D were isolated from breast cancers differing in biochemical background,
while HeLa, SiHa and C33A cells were from cervical cancers of various pathological histories, and
A2780 cells were isolated from ovarian cancer. Non-cancerous human fibroblast cells (MRC-5) was
additionally used to assess the cancer selectivity of the most effective compound. All cell lines were
purchased from European Collection of Cell Cultures (ECCAC, Salisbury, UK) except for SiHa and
C33A, which were obtained from LGC Standards GmbH (Wesel, Germany). Cells were cultivated
in minimal essential medium supplemented with 10% fetal bovine serum, 1% non-essential amino
acids and an antibiotic-antimycotic mixture. All media and supplements were obtained from Lonza
Group Ltd., (Basel, Switzerland). Near-confluent cancer cells were seeded onto a 96-well microplate
(5000 cells/well except for C33A and MDA-MB-361, which were seeded at 10,000/well) and, after
overnight standing, 200 µL new medium, containing the tested compounds at 10 and 30 µM, was
added. After incubation for 72 h at 37 ˝C in humidified air containing 5% CO2, the living cells were
assayed by the addition of 20 µL of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) solution. MTT was converted by intact mitochondrial reductase and precipitated as
purple crystals during a 4-h contact period. The medium was next removed and the precipitated
formazan crystals were dissolved in 100 µL of DMSO during a 60-min period of shaking at 37 ˝C.
Finally, the reduced MTT was assayed at 545 nm, using a microplate reader; wells with untreated
cells served as control [32]. In the case of the most active compounds (i.e., higher than 70% growth
inhibition at 30 µM), the assays were repeated with a set of dilutions, sigmoidal dose-response curves
were fitted to the determined data and the IC50 values (the concentration at which the extent of cell
proliferation was half that of the untreated control) were calculated by means of GraphPad Prism
4.0 (GraphPad Software, San Diego, CA, USA). All in vitro experiments were carried out on two
microplates with at least five parallel wells. Stock solutions of the tested substances (10 mM) were
prepared in DMSO. The highest DMSO content of the medium (0.3%) did not have any substantial
effect on the cell proliferation. Cisplatin (Ebewe Pharma GmbH, Unterach, Austria) was used as
positive control.
5. Conclusions
Novel antiproliferative triazolyl D-secoestrone derivatives were synthesized by introducing the
triazolylmethyl linker between the 3-OH and the benzyl or p-substituted benzyl protecting group.
The “clicking” of benzyl azides to the 3-propargyl-D-secoestrones led to potent antiproliferative
compounds. The synthesized derivatives differed at two sites of the molecules: in the orientation
of the angular methyl function and in the nature of the substituent present on the 3-OH group.
It can be stated that both variables substantially influenced the antiproliferative behavior. The 3-OH
derivatives displayed the lowest growth-inhibitory action. Etherification of the phenolic OH
group improved the cytostatic properties moderately, but the incorporation of the triazolylmethyl
linker between the protecting group and the 3-O nevertheless increased the inhibitory values of
the compounds substantially. 13β-Methyl derivatives proved to be more potent than their 13α
counterparts overall. As concerns the p-substituent on the N-benzyl ring, neither the presence of the
electron-withdrawing nor that of the electron-donating group appeared to be advantageous, in contrast
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with the unsubstituted derivative. It can be concluded that the combination of the 13β-methyl and
the 3-(N-benzyltriazolylmethoxy) group on the D-secoestrone scaffold intensifies the antiproliferative
potential. These compounds are the most potent cell-growth-inhibitor D-secoestrones reported to date.
Antiproliferative potential of 13α-D-secoestrone derivatives is a novel finding.
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